Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.

CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?

Crispr Therapeutics isn't without risks, but that shouldn't dissuade investors from a CRSP stock collar purchase for core positioning. The post Crispr Therapeutics Has Bullish DNA appeared first on InvestorPlace.

Crispr Therapeutics Has Bullish DNA

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR Therapeutics AG (CRSP) to Report Q2 Results: Wall Street Expects Earnings Growth

While the technologies that undergird CRSP stock is nothing short of mind-blowing, you should be aware of the ethical risks. The post Can CRISPR Therapeutics Stock Investors Steer Clear of Ethical Concerns?

Can CRISPR Therapeutics Stock Investors Steer Clear of Ethical Concerns?

CRISPR Therapeutics AG (CRSP) closed at $126.25 in the latest trading session, marking a -0.67% move from the prior day.

CRISPR Therapeutics AG (CRSP) Stock Moves -0.67%: What You Should Know

Beam Therapeutics

Editas Medicine

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week

Intellia Therapeutics

Gene editing could revolutionize the way we treat diseases. Along the way, it could also create substantial opportunity for related stocks.

The Top 3 Gene Editing Stocks to Own for the Next Decade

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a larger sell-off in the gene-editing companies drove the stock price down nearly 32% to its.

Will CRISPR Stock Rebound After A 10% Fall In A Week?

The company is lagging behind established pharmaceutical companies. Other cheaper alternatives are on the way.

Crispr Therapeutics: Get Ready To Bail Out

Alnylam Pharmaceuticals

BioNTech SE

Moderna

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Here's What Drove Gene Editing Stocks Higher This Week

Cellectis SA

Calyxt

Sangamo Therapeutics

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century appeared first on InvestorPlace.

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia. The post Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar appeared first on InvestorPlace.

Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar

AMC Entertainment

Clover Health Investments

GameStop

Senseonics Holdings

Wish

Workhorse Group

The broad markets saw a somewhat mixed start to the week with the Dow Jones Industrial Average lagging both the S&P 500 and Nasdaq.

Meme Stocks Get Off to a Strong Start As Nasdaq Hits New Highs

The stock price of Crispr Therapeutics AG (NASDAQ: CRSP) increased by over 10% pre-market. This is why it happened.

CRSP Stock Price Increases Over 10% Pre-Market: Why It Happened

Bionano Genomics

Gene editing stocks are getting a boost on Monday morning after Intellia Therapeutics said it was successful using CRISPR gene-editing therapy directed inside the body to an internal organ. The post Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks appeared first on InvestorPlace.

Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks

Torchlight Energy Resources

The broad markets saw another push higher on Thursday with the S&P 500 and Nasdaq setting new all-time highs in the session.

New All-Time Highs in Nasdaq and S&P 500: What This Means For Meme Stocks

BlackBerry

Palantir Technologies

The Dow climbed over 1% early on Monday as a result of a strong push from industrial stocks.

Monday's Crypto Breakdown and Meme Stock Meltdown

Canoo

Petco Health and Wellness

The Nasdaq climbed nearly 1% on Thursday as the result of a strong push from tech stocks.

Thursday's Major Meme Stock Action

CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.

CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases

CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a delivery mechanism for the company's gene-editing technology in familial amyotrophic lateral sclerosis (ALS) and rare neurodegenerative disorder Friedreich's ataxia. As part of the agreement, Capsida will pick up R&D responsibilities for the ALS program and chip away at capsid design for both programs.

CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases

- Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases -

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich's Ataxia

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has seen a solid 26% rise over the last twenty-one trading sessions, and we believe that the stock may continue to rally upward in the near term.

Despite A 26% Growth Over The Last Month CRISPR Stock May Continue To Rise

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.

CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data

Chipotle

Kinder Morgan

Wendy's

Autolus Therapeutics

Core Laboratories Inc

Cheniere Energy Partners

DHI Group

EnLink Midstream

Hess Midstream Partners

iMedia Brands

Tyler Technologies

Welltower

Monday's futures were relatively flat, with the Nasdaq looking the best out of the group with about a 0.2% gain.

Monday's Analyst Upgrades and Downgrades: Chipotle, CRISPR, Hess Midstream, iMedia, Kinder Morgan, Wendy's and More

Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and sickle cell disease. Presenting data from two trials at the European Hematology Association annual meeting, the companies announced that three-month follow-up data of 22 patients with genetic blood disorders indicated a “consistent and sustained” response to the experimental drug CTX001.

Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials

News for CRISPR Therapeutics Stock (CRSP)